Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Account Payables (2016 - 2025)

Spero Therapeutics' Change in Account Payables history spans 10 years, with the latest figure at -$702000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 157.73% year-over-year to -$702000.0; the TTM value through Dec 2025 reached -$6.6 million, down 211.56%, while the annual FY2025 figure was -$6.6 million, 211.56% down from the prior year.
  • Change in Account Payables reached -$702000.0 in Q4 2025 per SPRO's latest filing, down from $615000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q1 2022 to a low of -$5.5 million in Q1 2025.
  • Average Change in Account Payables over 5 years is -$23050.0, with a median of $120500.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: skyrocketed 5064.71% in 2024, then plummeted 428.26% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$2.1 million in 2021, then increased by 4.51% to -$2.0 million in 2022, then surged by 113.98% to $275000.0 in 2023, then soared by 342.18% to $1.2 million in 2024, then crashed by 157.73% to -$702000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Change in Account Payables are -$702000.0 (Q4 2025), $615000.0 (Q3 2025), and -$985000.0 (Q2 2025).